🔴 Humacyte is trading 5.55% down on October 8, 2026 amid biotech-sector weakness; direct cause remains unclear

Humacyte is trading at $0.45, down 5.55% on October 8; no clear company-specific announcement explaining the decline was identified.

• Barclays maintained a Hold rating and $0.50 price target in coverage reported October 7; it did not present a new catalyst for the session.
• Biotech ETF XBI fell 2.04% during the regular session, a potential sector headwind. Major indexes were only modestly lower, and available evidence does not establish the direct cause of Humacyte’s move.